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Abstract: New derivatives of phaeosphaeride A (PPA) were synthesized and characterized.
Anti-tumor activity studies were carried out on the HCT-116, PC3, MCF-7, A549, K562, NCI-H929,
Jurkat, THP-1, RPMI8228 tumor cell lines, and on the HEF cell line. All of the compounds synthesized
were found to have better efficacy than PPA towards the tumor cell lines mentioned. Compound 6 was
potent against six cancer cell lines, HCT-116, PC-3, K562, NCI-H929, Jurkat, and RPMI8226, showing
a 47, 13.5, 16, 4, 1.5, and 7-fold increase in anticancer activity comparative to those of etoposide,
respectively. Compound 1 possessed selectivity toward the NCI-H929 cell line (IC50 = 1.35± 0.69 µM),
while product 7 was selective against three cancer cell lines, HCT-116, MCF-7, and NCI-H929, each
having IC50 values of 1.65 µM, 1.80 µM and 2.00 µM, respectively.
Keywords: natural phaeosphaeride A; antitumor activity; human tumor cell lines; HEF cell line;
acute toxicity
1. Introduction
Modern chemotherapeutic treatment of malignant tumors is widely considered to have begun
approximately 75 years ago when researchers found that nitrogen mustard displayed anti-tumor
activity [1]. In more recent decades, leading research approaches have focused on the development of
new antitumor agents for targeted therapy, as well as combined treatment with immunotherapeutic
and chemotherapeutic agents [2]. Diversity, and in many cases, the genetic uniqueness of tumors, does
not allow for the development of universal and specific therapeutic treatment. As a result, the use
of non-specific chemotherapeutic treatment is still the principal therapeutic option used in patients.
Despite advances in cancer treatments, the disabling side effects and relative effectivity of these broad
antitumor drugs plagues scientists to urgently develop improved chemotherapeutic agents.
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Many chemotherapeutic agents used in clinical practice are developed from natural compounds
or their derivatives and analogs, e.g., etoposide, eribulin, paclitaxel, vincristine, vinblastine, topotecan,
cytarabine, doxorubicin, dactinomycin, and bleomycin [3–5]. These also include medicines developed
and introduced into clinical practice from the 1950s–1960s (vincristine, vinblastine, cytarabine, etc.),
as well as modern agents developed in the 2000’s (topotecan, eribulin). Many chemotherapeutic agents
based on natural analogs continue to undergo clinical studies to evaluate their effectiveness in the
treatment of various types of tumors, as drugs developed from natural compounds often show lower
toxicity and have higher target values towards malignant tumor cells [3]. While scientists continue to
research these compounds, these naturally derived drugs are already relevant in the market today,
with close to 40% of antitumor drugs approved by the FDA being of natural origin or semi-synthetic
derivatives of natural compounds. When we reexamine this number and consider only the use of
synthetic drugs, the analogues of natural compounds, the proportion of these antitumor agents are
estimated at 70% [6]. Clearly, nature remains an inexhaustible source of new substances and has vast
potential to aid in the fight against various tumors.
Here, phaeosphaeride A, produced by endophytic fungi from the genus Phaeosphaeria, was chosen
for its ability to inhibit the Signal Transducer and Activator of Transcription 3 (STAT3) signaling
pathway. The stereochemical configuration of this natural product had been established by total
synthesis of ent-phaeosphaeride A and phaeosphaeride A [7,8] and by X-ray diffraction [9]. High
incidence of STAT3 protein is characteristic of several oncological diseases like leukemia, multiple
myeloma, cancers of the breast and lung, as well as multiple carcinomas such as renal, prostate,
hepatocellular, ovarian, and pancreatic [10,11]. STAT3 also is shown to play an important role in
regulating cell growth and viability [10,12–15]. Therefore, phaeosphaeride A, and its derivatives, are
potentially promising anticancer agents for targeted therapy and combined treatments [10,11].
The results of the study in this article include information on the methods for the synthesis of
the phaeosphaeride A derivatives and their biological evaluation, including the measurements of the
cytotoxic effects and a preliminary assessment of acute toxicity in mice.
2. Results and Discussion
2.1. Chemistry
The synthesis of target compounds 1–8 is presented in Scheme 1. Mesylation of PPA with
MeSO2Cl and Et3N in CH2Cl2 gave the mesylate as a sole product, which was used in the next step
without purification.
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Scheme 1. Synthesis of compounds 1–8. Reagents and conditions: (a) MsCl, TEA, CH2Cl2, 0 °C, 1 h; (b) 
cyclic or primary amine, with or without TEA, acetonitrile or THF, room temperature or 70–75 °C. 
Scheme 1. Synthesis of compounds 1–8. Reagents and conditions: (a) MsCl, TEA, CH2Cl2, 0 ◦C, 1 h;
(b) cyclic or primary amine, with or without TEA, acetonitrile or THF, room temperature or 70–75 ◦C.
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Treatment of the mesylate with cyclic amines and (or without) TEA in acetonitrile (or THF) at
room temperature (or at 70–75 ◦C) or with primary amines in acetonitrile at room temperature gave
the corresponding amino derivatives in 11–27% yield with inversion occurring on the C-6 atom. The
ROESY spectra of the products showed a correlation between the methyl protons (H-15) and the
H-6 proton confirming the inversion of configuration of the C-6 atom (see Supplementary Material).
Product 6 was synthesized by our research group in 2017 with the present method doubling the total
yield [16]. Previously it was impossible to obtain the desired derivatives through chloroacetyl PPA
derivative from primary amines as those reactions proceeded solely at the exocyclic double bond
(unpublished data) [17].
2.2. Biological Evaluation
2.2.1. Cytotoxicity Assay Using 9 Tumor Cell Lines and HEF Cell Line
All newly synthesized PPA derivatives 1–8 were evaluated for their anti-proliferative activity
against human breast cancer MCF-7, human prostate adenocarcinoma PC-3, human colorectal cancer
HCT-116, human lung cancer A549, human chronic myelogenous leukemia K562, human acute
monocytic leukemia THP-1, human multiple myeloma RPMI8226, human acute T-cell leukemia Jurkat,
human multiple myeloma NCI-H929, and human embryonic fibroblasts HEF cell lines by MTT assays.
All cells were incubated with different concentrations of PPA derivatives for 72 h, with etoposide and
PPA used as reference compounds. The anticancer activity of the tested compounds was described as
the concentration of drug inhibiting 50% cell growth IC50 (Tables 1 and 2).
Table 1. IC50 values for the respective compounds when studied on the adhesive cell lines. Data was
expressed as the inhibitory ratio ± SD based on three independent experiments (n = 3).
Compound Adhesive Cell Cultures, IC50 (µM)
HCT-116 PC-3 MCF-7 A549 HEF
PPA 24.21 ± 0.75 32.14 ± 0.77 20.30 ± 0.8 41.10 ± 2.6 19.05 ± 0.25
1 3.68 ± 0.81 3.35 ± 0.92 4.10 ± 0.44 12.73 ± 0.40 22.30 ± 0.44
2 4.63 ± 0.04 5.55 ± 1.48 3.23 ± 1.07 15.14 ± 0.45 16.20 ± 0.26
3 2.90 ± 0.98 4.50 ± 1.56 3.05 ± 1.20 11.41 ± 0,19 15.19 ± 1.02
4 8.40 ± 0.24 6.37 ± 0.18 4.13 ± 0.23 12.65 ± 0.27 5.03 ± 0.15
5 12.93 ± 0.30 24.67 ± 1.24 35.71 ± 0.65 37.51 ± 1.33 53.11 ± 1.06
6 0.47 ± 0.01 0.20 ± 0.07 3.25 ± 0.64 10.11 ± 0.5 4.00 ± 0.17
7 1.65 ± 0.63 3.65 ± 0.64 1.80 ± 0.44 12.22 ± 0.2 22.30 ± 0.33
8 2.64 ± 0.05 4.53 ± 0.40 3.20 ± 0.52 9.40 ± 0.14 6.70 ± 0.23
Etoposide 22.00 ± 1.10 2.70 ± 0.05 9.60 ± 0.27 >100 >100
Table 2. IC50 values for the respective compounds when studied on the suspension cell lines. Data
were expressed as inhibitory ratio ± SD based on three independent experiments (n = 3).
Compound Suspension Cell Cultures, IC50 (µM)
K562 NCI-H929 Jurkat THP-1 RPMI8228
PPA 20.47 ± 1.46 6.50 ± 0.30 9.70 ± 0.42 19.10 ± 0.45 9.15 ± 0.64
1 3.25 ± 0.64 1.35± 0.69 2.75 ± 0.21 2.25 ± 0.21 3.97 ± 0.68
2 5.50 ± 0.57 2.05 ± 0.35 2.60 ± 0.99 2.30 ± 0.57 3.50 ± 0.82
3 6.70 ± 0.28 1.95 ± 0.21 3.15 ± 1.77 2.60 ± 0.57 2.70 ± 0.28
4 10.48 ± 0.41 2.35 ± 0.09 3.27 ± 0.07 3.32 ± 0.10 6.00 ± 0.13
5 14.13 ± 0.48 7.73 ± 0,25 10.10 ± 0.44 15.11 ± 0.36 16 ± 0.16
6 0.54± 0.03 0.23± 0.02 0.55± 0.29 2.05 ± 0.21 0.63± 0.23
7 6.03 ± 0.91 2.00± 0.26 2.73 ± 1.53 3.45 ± 0.21 3.35 ± 1.48
8 4.90 ± 2.40 1.87 ± 0.25 2.60 ± 1.13 2.10 ± 0.28 1.40 ± 0.28
Etoposide 8.47 ± 0.95 0.92 ± 0.03 0.88 ± 0.74 0.83 ± 0.21 4.60 ± 0.28
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Compound 6 was found to be the most potent against six cancer cell lines (0.47 µM for HCT-116,
0.2 µM for PC-3, 0.54 µM for K562, 0.23 µM for NCI-H929, 0.55 µM for Jurkat and 0.63 µM for
RPMI8226), which was 51, 160, 37, 28, 17.5, and 14.5-fold stronger than those of the reference compound
PPA, respectively (Figure 1).
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Figure 1. (a) The in vitro effects of compound 6 on the cell viability of human HCT-116 cell line; (b) The
in vitro effects of compound 6 on the cell viability of uman NCI-H929 cell line.
Compound 1 showed selectivity toward the NCI-H929 cell line (IC50 = 1.35 ± 0.69 µM) while
product 7 was selective against three cancer cell lines (IC50 was 1.65 µM, 1.80 µM and 2.00 µM to ards
HCT-116, MCF-7 and NCI-H929, r spectively). The results obtained indicate product 6 to be more
toxic than the positive control, etoposide, against HCT-116 (47-fold), PC-3 (13.5-f l ), K562 (16-fold),
NCI-H929 (4-fold), Jurkat (1.5-f ld) and RPMI8226 (7-fold) cancer cell lines. Human embry nic
fibroblasts were used as control.
2.2.2. Acute Intraperitoneal Toxicity Study
No adverse effects were found from compound 6 on body weight and food consumption. There
was no indication of morbidity, mortality, or lethal effects during the 14 days after i.p. administration
(intraperiotenal) in mice of two low doses (8.25 and 82.5 mg/kg). LD50 was not reached in all
experiments. Mortality (two of eight mice) was observed in the highest dose group (one was found
deceased on Day 2 and one on Day 3). No effect was observed on mean body weight or mass
coefficients (spleen, liver, heart, kidney, lung, thymus, and adrenal). No gross abnormalities were
observed in the organs tested. Maximum tolerated dose of 6 after i.p. injection in mice was equal to or
more than 82.5 mg/kg. Median lethal dose (LD50) of 6 has not been determined but is believed to be
more than 200 mg/kg. It can be concluded that compound 6 is less toxic co parative to etoposide.
Intraperitoneal LD50 of etoposide for mice is 64 mg/kg (RTECS # KC0190000).
3. Materials and Methods
3.1. Materials and Instruments
1H-NMR spectra were acquired on an AVANCE III 400 MHz NMR spectrometer (Bruker,
Rheinstetten, Germany) in CDCl3. Optical rotations were acquired on a Polaar 3005 Polarimeter
(Optical Activity, Huntingdon, Great Britain) using a 2.5 cm cell with a Na 589 nm filter and the
concentration of samples was denoted as c. Mass spectra data were acquired on a TSQ Quantum
Access Max Mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). High-resolution mass
spectra (HRMS) were acquired on a LTQ Orbitrap Velos spectrometer (Thermo Scientific) and on a
Bruker MicrOTOF. FTIR spectra were acquired on an IR Affinity-1 spectrometer (Shimadzu, Thermo
Scientific). Organic solvents used were dried by standard methods when necessary. Commercially
available reagents were used without further purification. All reactions were monitored by TLC with
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silica gel coated plates (EMD/Merck KGaA, Darmstadt, Germany), with visualization by UV light and
by charring with 0.1% ninhydrin in EtOH. Column chromatography was performed using Merck 60 Å
70–230 mesh silica gel. The optical density was determined using a Multiskan FC spectrophotometer
(Thermo Scientific) at a wavelength of 540 nm when using the MTT assay.
3.2. Chemical Syntheses
3.2.1. Synthesis of (2S,3S,4S)-3-Hydroxy-6-methoxy-3-methyl-7-methylene-5-oxo-2-pentyl-
2,3,4,5,6,7-hexahydropyrano[2,3-c]pyrrol-4-yl methanesulfonate
PPA (1 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 ◦C. Triethylamine (3.5 mmol) was
added followed by the dropwise addition of methanesulfonyl chloride (2.5 mmol). The mixture was
stirred at 0 ◦C for 1 h. The reaction was quenched by the addition of saturated NaHCO3 solution and
the mixture was extracted with dichloromethane (3 × 20 mL). The organic layer was washed with
water and brine, dried over magnesium sulfate, and concentrated in vacuo after filtration. Mesylate
was used in the next step without further purification. HRMS revealed an [M + H]+ion with exact
mass 376.14219, corresponding to the molecular formula C16H26NO7S.
3.2.2. General Procedure for the Synthesis of Compounds 1–5
A mixture of the crude (2S,3S,4S)-3-hydroxy-6-methoxy-3-methyl-7-methylene-5-oxo-2-pentyl-
2,3,4,5,6,7-hexahydropyrano[2,3-c]pyrrol-4-yl methanesulfonate (1 mmol) and an appropriate primary
amine (2 mmol) was stirred in dry acetonitrile (2 mL) at room temperature until consumption of
the starting material was complete as judged by TLC analysis (24–48 h). The reaction mixture was
diluted with ether (20 mL) and transferred to a separatory funnel. The layers were separated and the
aqueous layer was extracted with ether (3 × 20 mL). The organic extracts were combined, washed
with brine (2 × 20 mL), dried over magnesium sulfate, and concentrated in vacuo. The crude product
was purified by flash chromatography (DCM:methanol = 60:1).
(2S,3R,4R)-3-Hydroxy-6-methoxy-3-methyl-4-(methylamino)-7-methylene-2-pentyl-3,4,6,7-tetrahydro-pyrano
[2,3-c]pyrrol-5(2H)-one (1): Yield 17%, yellow oil. [α]20.0D = −120.36 (c 0.28, CH2Cl2). 1H-NMR (CDCl3)
δ 5.56 (m, 2H), 5.12 (s, 1H), 5.07 (s, 1H), 4.05 (m, 1H), 3.93 (s, 3H), 3.41 (m, 1H), 2.75 (s, 3H), 1.93 (m,
1H), 1.63 (m, 2H), 1.43–1.33 (m, 5H), 1.15 (s, 3H), 0.90 (m, 3H). 13C-NMR (CDCl3) δ 165.87 (s), 159.47
(s), 136.05 (s), 99.07 (s), 93.27 (s), 81.54 (s), 68.97 (s), 64.70 (s), 57.32 (s), 33.50 (s), 31.58 (s), 27.62 (s), 25.99
(s), 22.53 (s), 19.45 (s), 14.05 (s). IR (KBr) 3319, 2955, 2930, 2859, 1721, 1667, 1633, 1438, 1379, 1266, 1196,
1166, 1085, 979, 915 cm−1. HRMS [M + H]+ calcd for C16H27N2O4 311.19653, found 311.1953.
(2S,3R,4R)-3-Hydroxy-4-[(2-hydroxyethyl)amino]-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7-tetra-
hydropyrano[2,3-c]pyrrol-5(2H)-one (2): Yield 25%, yellow oil. [α]20.0D = −99.54 (c 0.22, CH2Cl2). 1H-NMR
(CDCl3) δ 5.09 (s, 1H), 5.04 (s, 1H), 3.93 (m, 4H), 3.61 (m, 2H), 3.12 (s, 1H), 3.06–2.91 (m, 2H), 1.94 (m,
1H), 1.65–1.58 (m, 2H), 1.35 (m, 6H), 1.06 (s, 3H), 0.91 (s, 3H). 13C-NMR (CDCl3) δ 167.38 (s), 157.36
(s), 136.27 (s), 104.10 (s), 92.86 (s), 82.53 (s), 69.28 (s), 64.71 (s), 61.07 (s), 54.14 (s), 52.07 (s), 31.66 (s),
27.47 (s), 26.28 (s), 22.57 (s), 18.58 (s), 14.08 (s). IR (KBr) 3322, 2954, 2927, 2857, 1718, 1633, 1547, 1458,
1437, 1378, 1263, 1191, 1117, 1081, 978, 914 cm−1. HRMS [M + H]+ calcd for C17H29N2O5 341.20710,
found 341.2060.
(2S,3R,4R)-3-Hydroxy-4-[(4-hydroxybutyl)amino]-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7-tetra-
hydropyrano[2,3-c]pyrrol-5(2H)-one (3): Yield 20%, yellow oil. [α]20.0D = −89.80 (c 0.51, CH2Cl2). 1H-NMR
(CDCl3) δ 5.11 (d, J = 1.2 Hz, 1H), 5.05 (d, J = 1.3 Hz, 1H), 4.94 (m, 3H), 4.05 (m, 1H), 3.93 (s, 3H),
3.80–3.50 (m, 2H), 3.36 (s, 1H), 3.27–3.12 (m, 1H), 3.06–2.87 (m, 1H), 1.95 (m, 1H), 1.78 (m, 2H), 1.69–1.55
(m, 4H), 1.45–1.33 (m, 5H), 1.12 (s, 3H), 0.90 (m, 3H). 13C-NMR (CDCl3) δ 166.37 (s), 158.18 (s), 136.38
(s), 102.16 (s), 92.59 (s), 82.14 (s), 68.78 (s), 64.64 (s), 62.26 (s), 55.97 (s), 48.77 (s), 31.64 (s), 30.14 (s), 27.61
(s), 26.12 (s), 22.57 (s), 19.15 (s), 14.08 (s). IR (KBr) 3292, 2927, 2858, 1712, 1632, 1548, 1438, 1379, 1191,
1083, 989, 914 cm−1. HRMS [M + H]+ calcd for C19H33N2O5 369.23840, found 369.2373.
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(2S,3R,4R)-4-(Allylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7-tetrahydropyrano-
[2,3-c]pyrrol-5(2H)-one (4): Yield 14%, yellow oil. [α]20.0D = −157.50 (c 0.31, CH2Cl2). 1H-NMR (CDCl3) δ
5.89 (ddt, J = 12.2, 10.1, 6.1 Hz, 1H), 5.25 (dd, J = 17.2, 1.3 Hz, 1H), 5.12 (m, 1H), 5.03 (d, J = 1.3 Hz, 1H),
4.99 (d, J = 1.3 Hz, 1H), 3.93 (s, 3H), 3.78–3.66 (m, 1H), 3.58–3.49 (m, 1H), 3.44 (ddd, J = 13.8, 4.6, 1.2 Hz,
1H), 3.03 (s, 1H), 1.94 (m, 1H), 1.60 (m, 2H), 1.43–1.35 (m, 5H), 1.06 (s, 3H), 0.91 (m, 3H). 13C-NMR
(CDCl3) δ 166.68 (s), 156.86 (s), 136.78 (s), 136.06 (s), 117.05 (s), 105.17 (s), 91.79 (s), 82.65 (s), 68.23 (s),
64.59 (s), 54.92 (s), 52.14 (s), 31.69 (s), 27.63 (s), 26.29 (s), 22.57 (s), 18.72 (s), 14.09 (s). IR (KBr) 3314,
2955, 2928, 2858, 1720, 1668, 1634, 1437, 1367, 1232, 1192, 1087, 992, 919 cm−1. HRMS [M + H]+ calcd
for C18H29N2O4 337.21218, found 337.2111.
(2S,3R,4R)-4-(benzylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7-tetrahydro-pyrano
[2,3-c]pyrrol-5(2H)-one (5): Yield 17%, yellow oil. [α]20.0D = −137.81 (c 0.43, CH2Cl2). 1H-NMR (CDCl3) δ
7.39–7.26 (m, 5H), 5.04 (d, J = 1.4 Hz, 1H), 5.00 (d, J = 1.4 Hz, 1H), 4.30 (d, J = 12.3 Hz, 1H), 3.94 (m, 4H),
3.53 (m, 1H), 3.12 (s, 1H), 1.93 (m, 1H), 1.61 (m, 2H), 1.34 (m, 5H), 1.06 (s, 3H), 0.90 (m, 3H). 13C-NMR
(CDCl3) δ 166.78 (s), 156.89 (s), 139.35 (s), 136.81 (s), 128.61 (d, J = 8.7 Hz), 127.47 (s), 105.30 (s), 91.89
(s), 82.70 (s), 68.26 (s), 64.63 (s), 55.37 (s), 53.62 (s), 31.68 (s), 27.63 (s), 26.27 (s), 22.56 (s), 18.82 (s), 14.07
(s). IR (KBr) 3309, 2955, 2927, 2858, 1720, 1633, 1454, 1436, 1378, 1232, 1192, 1086, 978, 914 cm−1. HRMS
[M + H]+ calcd for C22H31N2O4 387.22783, found 387.2262.
3.2.3. General Procedure for the Synthesis of Compounds 6–8
A mixture of the crude (2S,3S,4S)-3-hydroxy-6-methoxy-3-methyl-7-methylene-5-oxo-2-pentyl-
2,3,4,5,6,7-hexahydropyrano[2,3-c]pyrrol-4-yl methanesulfonate (1 mmol), the corresponding cyclic
amine (1.5 mmol) and triethylamine (3 mmol) was stirred in dry acetonitrile (2 mL) at room temperature
until consumption of the starting material was complete as judged by TLC analysis (24–48 h). The
reaction mixture was quenched with water and extracted with EtOAc (2 × 20 mL). The organic extract
was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The crude product
was purified by flash chromatography (DCM/methanol).
3.2.4. Alternative General Procedure for the Synthesis of Compounds 6–8
A mixture of the crude (2S,3S,4S)-3-hydroxy-6-methoxy-3-methyl-7-methylene-5-oxo-2-pentyl-
2,3,4,5,6,7-hexahydropyrano[2,3-c]pyrrol-4-yl methanesulfonate (1 mmol) and the corresponding cyclic
amine (5 mmol) in dry THF (2 mL) was heated at 70–75 ◦C in a sealed tube for 18 h. The mixture
was cooled to room temperature, filtered, and the THF solution was diluted with saturated sodium
bicarbonate solution (20 mL). The resulting mixture was extracted with DCM (3 × 20 mL). The organic
extracts were washed with water, dried with magnesium sulfate, and concentrated in vacuo. The
crude product was purified by flash chromatography (DCM/methanol).
(2S,3R,4R)-3-Hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-4-pyrrolidin-1-yl-3,4,6,7-tetrahydro-pyrano
[2,3-c]pyrrol-5(2H)-one (6): Yield 27%, yellow oil. [α]20.0D = −176.52 (c 0.40, CH2Cl2). 1H-NMR (CDCl3)
δ 5.40 (s, 1H), 5.02 (d, J = 1.4 Hz, 1H), 4.98 (d, J = 1.4 Hz, 1H), 3.92 (s, 3H), 3.64 (d, J = 9.9 Hz, 1H), 3.31
(s, 1H), 3.10–2.55 (m, 4H), 2.03–1.89 (m, 1H), 1.84–1.70 (m, 4H), 1.69–1.52 (m, 2H), 1.45–1.29 (m, 5H),
1.05 (s, 3H), 0.91 (t, J = 6.7 Hz, 3H). 13C-NMR (CDCl3) δ 167.11 (s), 158.44 (s), 137.00 (s), 101.65 (s), 91.38
(s), 83.60 (s), 68.00 (s), 64.41 (s), 59.55 (s), 31.73 (s), 28.21 (s), 26.43 (s), 23.91 (s), 22.55 (s), 19.66 (s), 14.04
(s). IR (KBr) 3430, 2957, 2930, 2860, 1722, 1633, 1438, 1190, 1144 cm−1. HRMS [M + H]+, calcd. for
C19H31N2O4 351.227834, found 351.22733.
(2S,3R,4R)-3-Hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-4-(4-pyrrolidin-1-ylpiperidin-1-yl)-3,4,6,7-
tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (7): Yield 11%, yellow oil. [α]20.0D = −115.82 (c 0.41, CH2Cl2).
1H-NMR (CDCl3) δ 5.05 (s, 1H), 5.00 (s, 1H), 3.91 (s, 3H), 3.56 (m, 1H), 3.29–2.91 (m, 8H), 2.81 (m, 1H),
2.65 (s, 1H), 2.27 (t, J = 10.9 Hz, 1H), 2.11–1.83 (m, 9H), 1.69–1.48 (m, 2H), 1.35 (s, 5H), 1.02 (s, 3H), 0.91
(s, 3H). 13C-NMR (CDCl3) δ 167.08 (s), 158.19 (s), 136.87 (s), 101.35 (s), 91.69 (s), 83.39 (s), 68.22 (s),
64.49 (s), 62.51 (s), 61.35 (s), 55.67 (s), 51.39 (s), 49.52 (s), 32.19 (s), 31.74 (s), 28.29 (s), 26.44 (s), 23.20 (s),
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22.57 (s), 19.96 (s), 14.08 (s). IR (KBr) 3213, 2928, 2857, 2782, 1724, 1669, 1635, 1437, 1377, 1354, 1321,
1193, 1150, 1126, 1085, 979 cm−1. HRMS [M + H]+ calcd for C24H40N3O4 434.30133, found 434.3009.
(2S,3R,4R)-3-Hydroxy-4-(4-hydroxypiperidin-1-yl)-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7-tetra-
hydropyrano[2,3-c]pyrrol-5(2H)-one (8): Yield 16%, yellow oil. [α]20.0D = −111.11 (c 0.36, CH2Cl2).
1H-NMR (CDCl3) δ 5.17 (s, 1H), 5.03 (d, J = 1.1 Hz, 1H), 5.00 (d, J = 1.1 Hz, 1H), 3.93 (s, 3H), 3.68 (s,
1H), 3.59 (m, 1H), 3.02 (s, 1H), 2.87 (s, 2H), 2.35 (s, 1H), 2.03–1.85 (m, 3H), 1.68–1.50 (m, 6H), 1.35 (m,
5H), 1.05 (s, 3H), 0.91 (m, 3H). 13C-NMR (CDCl3) δ 167.01 (s), 158.15 (s), 136.85 (s), 101.35 (s), 91.75 (s),
83.35 (s), 68.20 (s), 64.53 (s), 62.45 (s), 35.20 (s), 31.79 (s), 28.35 (s), 26.48 (s), 22.58 (s), 20.00 (s), 14.09 (s).
IR (KBr) 3213, 2926, 2855, 1720, 1671, 1634, 1547, 1438, 1375, 1139, 1066, 1045 cm−1. HRMS [M + H]+
calcd for C20H33N2O5 381.23840, found 381.2377.
3.3. Bio-Evaluation Methods
3.3.1. In-Vitro Cytotoxicity Study (MTT Assay)
MCF-7 (breast cancer), PC-3 (prostate adenocarcinoma), HCT-116 (colorectal cancer cell), A549
(lung cancer), K562 (chronic myelogenous leukemia), THP-1 (acute monocytic leukemia), and
RPMI8226 (multiple myeloma), Jurkat (acute T-cell leukemia), HEF (human embryonic fibroblasts)
was purchased from the Russian Academy of Sciences Cells Bank (Institute of Cytology of the Russian
Academy of Sciences, Saint Petersburg, Russian Federation). Multiple myeloma cell line NCI-H929
was purchased from ATCC (USA). The MCF-7, A549 and HEF (human embryonic fibroblasts) were
cultured in DMEM medium. Other cell lines were cultured in RPMI1640 medium, (PanEco, Russia)
supplemented with 10% fetal bovine serum (GE Healthcare LifeSciences, São Paulo, Brazil), and
gentamicin at a concentration of 40 µg/mL and cultured at 37 ◦C in a humidified atmosphere containing
5% CO2. All experiments were performed with cells at passages 3 to 7 in the logarithmic phase
of growth.
Cells were seeded into 96-well plates of 5 × 103 for adhesive cultures and 20 × 103 for suspension
cultures per well in 90 µL and 135 µL of culture medium, respectively. The test substances were
dissolved in DMSO to a concentration of 1 × 10−2 M. For subsequent dilution of the substances, a
serum-free culture medium was used as the diluent. Final concentration of DMSO in wells was no
more than 1%. It was found that this concentration of DMSO didn’t affect the cells. Substances were
added to the cells in 3–4 replicates after 24 h for adhesive cultures and immediately for suspension
cultures. 10–15 µL of serum-free medium was added to the control wells with non-exposed cells. Cells
were cultured for 72 h at 37 ◦C in an atmosphere of 5% CO2.
3.3.2. Experimental Animals
Six to eight-week-old outbreed male mice were purchased from the Rappolovo Animal Farm of
the Russian Academy of Sciences. Animals were group housed in solid bottom polycarbonate cages
(3–5 animals/cage) and provided with sterilized pelleted food and pure water ad libitum.
3.3.3. Ethical Guidelines
Animal care and protocols of the study were conducted in compliance with ethical standards
and recommendations for the human treatment of animals used in experimental and other scientific
purposes according to the European Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes (and protocol of amendment ETS No 170), the National
Standard of the Russian Federation GOST R-53434-2009, “Principles of Good Laboratory Practice,” and
by the order of the Ministry of Health of the Russian Federation 01.04.2016, No 199n «On approval of
the rules of good laboratory practice».
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3.3.4. Acute Intraperitoneal Toxicity Study
Thirty mice were randomly assigned to the acute toxicity study. Animals in experimental groups
(8 per/group) received a dose formulation containing compound 6 solution in 5% DMSO at various
dosages (8.25, 82.5 and 200 mg/kg) via single i.p. injection. Mice in the control group treated with
vehicle (5% DMSO). The location of the i.p. injection was in the lower left abdominal quadrant. Volume
of injection did not exceed 250 µL. After treatments, the following parameters and end points were
evaluated for 14 days: mortality, clinical signs, body weight, food consumption, locomotion, salivation,
diarrhea, and lethargy. The maximum tolerated dose in this study is defined as the highest dose
that will be tolerated and not produce major life-threatening toxicity for the study duration [18]. All
experimental procedures were performed according to the principles and guidelines for the care and
use of laboratory animals. The animals were sacrificed by carbon dioxide asphyxiation and cervical
dislocation. All efforts were made to minimize suffering. Post mortem evaluation included gross
examination for all animals at terminal necropsy and calculation of organ mass coefficients. No
histopathological examinations were performed.
4. Conclusions
In summary, a series of PPA derivatives were synthesized via mesylation and amination. Some
of these derivatives represent a promising class of cytotoxic agents with potential therapeutic values.
Compound 6 demonstrated the highest cytotoxicity and was less toxic when used in vivo compared
with the clinically used etoposide.
Supplementary Materials: 1H-NMR, 13C-NMR, 1H-1H ROESY and HRMS of these compounds are available in
the supplementary materials.
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